MTCRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 6月 2023 @ 04:11):

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...

Stats
本日の出来高	83 889.00
平均出来高	52 473.00
時価総額	25.48M
EPS	$0 ( 2023-11-13 )
Last Dividend	$0.580 ( 2023-06-21 )
Next Dividend	$0 ( N/A )
P/E	-0.564
ATR14	$0.0160 (2.75%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-23	Klassen Preston	Sell	842 211	Common Stock
2023-03-23	Klassen Preston	Sell	842 211	Stock Option (right to buy)
2023-01-26	York Michael	Sell	107 054	Common Stock
2023-01-26	Klassen Preston	Sell	380 605	Common Stock
2022-12-21	Leonard Braden Michael	Buy	120 099	Common Stock

INSIDER POWER
-16.10
Last 97 transactions
Buy: 12 877 287 \| Sell: 12 262 808

ボリューム相関

長: -0.64 (weak negative)

短: 0.81 (strong)

Signal:(57.111) Same movement expected

Metacrine, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Metacrine, Inc. 相関 - 通貨/商品

-0.39
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

-0.04
( neutral )

0.48
( neutral )

Metacrine, Inc. 財務諸表

Annual	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.436

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Metacrine, Inc. Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.580 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Metacrine, Inc. Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.580	2023-06-21
Last Dividend	$0.580	2023-06-21
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.580	--
Avg. Dividend % Per Year	43.27%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$1.160 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.580	129.80%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.766	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.835	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	13.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	9.85	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.177	-1.500	7.06	-10.00	[0 - 0.6]
interestCoverageTTM	-50.81	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
freeCashFlowPerShareTTM	-1.120	2.00	-0.560	-1.120	[0 - 20]
debtEquityRatioTTM	0.246	-1.500	9.01	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.34	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.578

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.400	1.000	-0.141	0	[1 - 100]
returnOnEquityTTM	-0.835	2.50	-6.68	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.120	2.00	-0.373	-1.120	[0 - 30]
dividendYielPercentageTTM	99.76	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-0.413

Metacrine, Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.